Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.

J Exp Clin Cancer Res · 2015 · PMC4320471 · PMID 25591549

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

borderline significantp = 0.059so close (0.05 < p ≤ 0.1)

Polymorphism p.Gln141Lys in the ABCG2 gene, borderline significant (OR 0.64; 95% CI 0.40-1.02; p = 0.059), decreased the risk of ovarian cancer for heterozygotes.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.